Russia can earn $10-15 billion in 2021 from sales of anti-COVID19 vaccine Sputnik V, reports RT, citing Alpari specialists information and Analytical Center.
In addition, over two years of deliveries of the drug abroad, the country’s revenue can reach $30 billion, experts say. They note that such indicators are comparable to the main items of Russian exports. Economists do not exclude that in the next few years, the implementation of the coronavirus vaccine will become one of the major areas of non-resource supply to Russia to other countries.
“The total revenue from the sale of the drug may be about $30 billion. Given that everyone wants to burn and vaccinate, respectively, we will receive about half of this amount this year and half in the next, “said Alexander Razuvaev, head of the analytical center.
According to the latest data from the Russian Direct Investment Fund, the Sputnik V vaccine has been approved in 59 countries with a total population of over 1.5 billion people. The cost of one dose of the drug for international markets is less than $10 (two doses are needed to vaccinate one person).
